NCT04012255View on ClinicalTrials.gov

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

August 30, 2019

Study Completion Date

October 22, 2019

Conditions
OverweightObesity
Interventions
DRUG

Semaglutide (administered by DV3396 pen)

Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks

DRUG

Semaglutide (administered by PDS290 pen)

Increasing doses of semaglutide given sc in the stomach for 21 weeks

Trial Locations (2)

41460

Novo Nordisk Investigational Site, Neuss

55116

Novo Nordisk Investigational Site, Mainz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY